Drug-targeting strategies in cancer therapy
- 1 February 2001
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Genetics & Development
- Vol. 11 (1), 104-110
- https://doi.org/10.1016/s0959-437x(00)00164-7
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Doxorubicin Represses CARP Gene Transcription Through the Generation of Oxidative Stress in Neonatal Rat Cardiac Myocytes: Possible Role of Serine/Threonine Kinase-dependent PathwaysJournal of Molecular and Cellular Cardiology, 2000
- Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein KinasesPublished by Elsevier BV ,2000
- Secreted human β-glucuronidase: a novel tool for gene-directed enzyme prodrug therapyGene Therapy, 2000
- Distribution Characteristics of Carboxymethylpullulan-Peptide-Doxorubicin Conjugates in Tumor-Bearing Rats: Different Sequence of Peptide Spacers and Doxorubicin Contents.Biological & Pharmaceutical Bulletin, 2000
- Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drugEuropean Journal Of Cancer, 1999
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenograftsEuropean Journal Of Cancer, 1998
- Intensely Cytotoxic Anthracycline Prodrugs: GlucuronidesJournal of Medicinal Chemistry, 1997
- Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrugAnti-Cancer Drugs, 1996
- Clinical Pharmacokinetics of DoxorubicinClinical Pharmacokinetics, 1988